IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Appl. No.

: National Phase Entry of PCT/EP03/10718

Applicant

: POZZI et al

Filed

: Herewith

TC/A.U. Examiner

Docket No. Customer No.: 6449

: 2965-195

Confirmation No. :

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

In compliance with applicants duty of disclosure under 37 C.F.R. 1.56, enclosed is a copy of the International Search Report in the corresponding international application. The relevance of the references is noted in the International Search Report.

In the event that any fees are due with this paper, please charge our Deposit Account No. 02-2135.

Βy Robert B. Murray

Attorney for Applicant

Respectfully submitted,

Registration No. 22,980

ROTHWELL, FIGG, ERNST & MANBECK

1425 K. Street, Suite 800 Washington, D.C. 20005

Telephone: (202) 783-6040

RBM/cb

JC13 Rec'd PCT/PTO 3	MAR	200
----------------------	-----	-----

				Complete if Known 10/529649			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	New Application			
		Filing Date	Herewith .				
		First Named Inventor	POZZI et al				
				Group Art Unit			
		Examiner Name					
		Confirmation No.					
Sheet		of		Attorney Docket Number	2965-195		

Examiner Initials*	Cite No. ¹	Office ³							
		Office ³ Number ⁴ Code		Kind ⁵ (if known)		Name of Pater Cited	ntee or Applicant of Document	Date of Publication of Cited Document MM-DD-YYYY	Τ,
	1.	wo	98/45299		Α	Biochemie Gr	nbH	10/15/98	
	2.	wo	97/24358		A1	Hanmi Pharm	aceutical Co., Ltd.	7/10/97	
	3.	wo	02/098884		A1	Hanmi Pharm	aceutical Co., Ltd.	12/12/02	
									Г
									T
									T
	-			1					一
							-		
				_					
xaminer							Date		Щ

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

JC13 Rec'd PCT/PTO 31	MAK	ZUUS
-----------------------	-----	------

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Complete if Know 10/520640			
		Application Number	New Application		
			Filing Date	Herewith	
		First Named Inventor	POZZI et al		
			Group Art Unit		
			Examiner Name		
			Confirmation No.		
Sheet	of		Attorney Docket Number	2965-195	

NON PATE	NT LITE	RATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				
	4.	OKAMOTO et al., "Degradation Kinetics and Isomerization of Cefdinir, A New Oral Cephalosporin, in Aqueous Solution", Journal of Pharmaceutical Sciences, Sept. 1996, pgs. 976-983, Vol. 85 (9).				
			_			
			!			
			i			
Examiner Signature		Date Considered	-			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.